Program Schedule

22
New Era of Hepatitis C Management

Thursday, October 9, 2014: 8:30 AM-10:00 AM
Room: The Pennsylvania Convention Center: 103-ABC

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • describe available methods to determine liver disease stage in patients with chronic HCV infection
  • interpret data from clinical trials for the treatment of patients with chronic HCV infection
  • discuss the challenges and opportunities for HCV infection from a global public health perspective

Target Audience: Pharmacists, Nurses, Members-in-training, Infectious diseases physicians, HIV specialists, HIV clinicians, Fellows, Epidemiologists, Clinicians, Academicians, Public health practitioners

Tracks: Global ID, Adult ID

Moderators:  Mark Sulkowski, MD, Johns Hopkins University School of Medicine and Eliot Godofsky, MD, Bach and Godofsky

Presentations:
8:50 AM
64
HCV Treatment 2014 and Beyond
Arthur Kim, MD, FIDSA
9:10 AM
65
9:30 AM
66
Panel Discussion
Arthur Kim, MD, FIDSA
9:40 AM
67
Panel Discussion
David Thomas, MD, MPH, FIDSA

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 CreditTM

ACPE Credits:

ACPE Number:

Disclosures:

M. Sulkowski, AbbVie: Investigator and Scientific Advisor, Consulting fee and Research grant
BMS: Investigator and Scientific Advisor, Consulting fee and Research support
Gilead: Investigator and Scientific Advisor, Consulting fee and Research support
Janssen: Investigator and Scientific Advisor, Consulting fee and Research support
Merck: Investigator and Scientific Advisor, Consulting fee and Research support

E. Godofsky, AbbVie: Research Contractor and Scientific Advisor, Consulting fee and Research support
Janssen Therapeutics: Research Contractor and Scientific Advisor, Consulting fee and Research support
Gilead Sciences: Research Contractor and Scientific Advisor, Consulting fee and Research support
Anadys: Research Contractor, Research support
Achillion: Research Contractor, Research support
Boeringer Ingelheim: Research Contractor, Research support
Genentech: Scientific Advisor and Speaker's Bureau, Consulting fee
Merck & Co: Research Contractor, Research support
Noavartis: Research Contractor, Research support
Vertex Pharmaceuticals: Research Contractor, Research support

D. Thomas, None

A. Kim, Gilead Sciences: Consultant and Investigator, Consulting fee and Research support
Abbvie Pharmaceuticals, Inc.: Consultant, Consulting fee
Bristol-Myers Squibb: Investigator, Research support

D. Thomas, None

A. Kim, Gilead Sciences: Consultant and Investigator, Consulting fee and Research support
Abbvie Pharmaceuticals, Inc.: Consultant, Consulting fee
Bristol-Myers Squibb: Investigator, Research support

S. Mehta, None

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

Sponsoring Societies:

© 2014, idweek.org. All Rights Reserved.

Follow IDWeek